|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang DX, Dai YD, Yuan SX and Tao L:
Prognostic factors in patients with pancreatic cancer. Exp Ther
Med. 3:423–432. 2012.PubMed/NCBI
|
|
3
|
Cao H, Le D and Yang LX: Current status in
chemotherapy for advanced pancreatic adenocarcinoma. Anticancer
Res. 33:1785–1791. 2013.PubMed/NCBI
|
|
4
|
Arslan C and Yalcin S: Current and future
systemic treatment options in metastatic pancreatic cancer. J
Gastrointest Oncol. 5:280–295. 2014.PubMed/NCBI
|
|
5
|
Di Marco M, Di Cicilia R, Macchini M,
Nobili E, Vecchiarelli S, Brandi G and Biasco G: Metastatic
pancreatic cancer: Is gemcitabine still the best standard
treatment? (Review). Oncol Rep. 23:1183–1192. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
De Felice F, Musio D, Raffetto N and
Tombolini V: Neoadjuvant strategy as initial treatment in
resectable pancreatic cancer: concrete evidence of benefit.
Anticancer Res. 34:4673–4676. 2014.PubMed/NCBI
|
|
7
|
Yutani S, Komatsu N, Yoshitomi M, Matsueda
S, Yonemoto K, Mine T, Noguchi M, Ishihara Y, Yamada A, Itoh K and
Sasada T: A phase II study of a personalized peptide vaccination
for chemotherapy-resistant advanced pancreatic cancer patients.
Oncol Rep. 30:1094–1100. 2013.PubMed/NCBI
|
|
8
|
Han ZT, Zhu XX, Yang RY, Sun JZ, Tian GF,
Liu XJ, Cao GS, Newmark HL, Conney AH and Chang RL: Effect of
intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA)
in patients with myelocytic leukemia: preliminary studies on
therapeutic efficacy and toxicity. Proc Natl Acad Sci USA.
95:5357–5361. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Strair RK, Schaar D, Goodell L, Aisner J,
Chin KV, Eid J, Senzon R, Cui XX, Han ZT, Knox B, Rabson AB, Chang
R and Conney A: Administration of a phorbol ester to patients with
hematological malignancies: preliminary results from a phase I
clinical trial of 12-O-tetradecanoylphorbol-13-acetate. Clin Cancer
Res. 8:2512–2518. 2002.PubMed/NCBI
|
|
10
|
Schaar D, Goodell L, Aisner J, Cui XX, Han
ZT, Chang R, Martin J, Grospe S, Dudek L, Riley J, Manago J, Lin Y,
Rubin EH, Conney A and Strair RK: A phase I clinical trial of
12-O-tetradecanoylphorbol-13-acetate for patients with
relapsed/refractory malignancies. Cancer Chemother Pharmacol.
57:789–795. 2006. View Article : Google Scholar
|
|
11
|
Zheng X, Ryan A, Patel N, Klemons S,
Hansson A, Shih WJ, Lin Y, Huberman E, Chang RL and Conney AH:
Synergistic stimulatory effect of
12-O-tetradecanoylphorbol-13-acetate and capsaicin on macrophage
differentiation in HL-60 and HL-525 human myeloid leukemia cells.
Int J Oncol. 26:441–448. 2005.PubMed/NCBI
|
|
12
|
Zheng X, Chang RL, Cui XX, Avila GE,
Hebbar V, Garzotto M, Shih WJ, Lin Y, Lu SE, Rabson AB, Kong AN and
Conney AH: Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in
combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells
cultured in vitro or grown as xenograft tumors in immunodeficient
mice. Clin Cancer Res. 12:3444–3451. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Avila GE, Zheng X, Cui XX, Ryan AD,
Hansson A, Suh J, Rabson AB, Chang RL, Shih WJ, Lin Y, Crowell P,
Lu YP, Lou YR and Conney AH: Inhibitory effects of
12-O-tetradecanoylphorbol-13-acetate alone or in combination with
all-trans retinoic acid on the growth of cultured human pancreas
cancer cells and pancreas tumor xenografts in immunodeficient mice.
J Pharmacol Exp Ther. 315:170–187. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bond JA, Gescher AJ, Verschoyle RD,
Lemoine NR, Errington R, Wiltshire M, Smith PJ and Wynford Thomas
D: Cytotoxic action of phorbol esters on human pancreatic cancer
cells. Int J Cancer. 121:1445–1454. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Salabat MR, Ding XZ, Flesche JB, Ujiki MB,
Robin TP, Talamonti MS, Bell RH Jr and Adrian TE: On the mechanisms
of 12-O-tetradecanoylphorbol-13-acetate-induced growth arrest in
pancreatic cancer cells. Pancreas. 33:148–155. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Detjen KM, Brembeck FH, Welzel M, Kaiser
A, Haller H, Wiedenmann B and Rosewicz S: Activation of protein
kinase C alpha inhibits growth of pancreatic cancer cells via
p21(cip)-mediated G(1) arrest. J Cell Sci. 113:3025–3035. 2000.
|
|
17
|
Zheng X, Cui XX, Gao Z, Verano M, Huang
MT, Liu Y, Rabson AB and Conney AH: Effects of
12-O-tetradecanoylphorbol-13-acetate in combination with
gemcitabine on Panc-1 pancreatic cancer cells cultured in vitro or
Panc-1 tumors grown in immunodeficient mice. Int J Oncol.
41:2269–2275. 2012.PubMed/NCBI
|
|
18
|
Carbone C and Melisi D: NF-κB as a target
for pancreatic cancer therapy. Expert Opin Ther Targets. 16(Suppl
2): S1–S10. 2012. View Article : Google Scholar
|
|
19
|
Hansson A, Marín YE, Suh J, Rabson AB,
Chen S, Huberman E, Chang RL, Conney AH and Zheng X: Enhancement of
TPA-induced growth inhibition and apoptosis in myeloid leukemia
cells by BAY 11-7082, an NF-kappaB inhibitor. Int J Oncol.
27:941–948. 2005.PubMed/NCBI
|
|
20
|
Zheng X, Chang RL, Cui XX, Avila G, Huang
MT, Liu Y, Kong AN, Rabson AB and Conney AH: Inhibition of
NF-kappaB by (E)3-[(4-methylphenyl)-sulfonyl]-2-propenenitrile
(BAY11-7082; BAY) is associated with enhanced
12-O-tetradecanoylphorbol-13-acetate-induced growth suppression and
apoptosis in human prostate cancer PC-3 cells. Int J Oncol.
32:257–264. 2008.
|
|
21
|
Matsuno T, Kariya R, Yano S, Morino-Koga
S, Taura M, Suico MA, Shimauchi Y, Matsuyama S, Okamoto Y, Shuto T,
Kai H and Okada S: Diethyldithiocarbamate induces apoptosis in
HHV-8-infected primary effusion lymphoma cells via inhibition of
the NF-κB pathway. Int J Oncol. 40:1071–1078. 2012.
|
|
22
|
Cvek B and Dvorak Z: Targeting of nuclear
factor-kappaB and proteasome by dithiocarbamate complexes with
metals. Curr Pharm Des. 13:3155–3167. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Suh JJ, Pettinati HM, Kampman KM and
O’Brien CP: The status of disulfiram: a half of a century later. J
Clin Psychopharmacol. 26:290–302. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Eneanya DI, Bianchine JR, Duran DO and
Andresen BD: The actions of metabolic fate of disulfiram. Annu Rev
Pharmacol Toxicol. 21:575–596. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Langeland BT and McKinley-McKee JS: The
effects of disulfiram on equine hepatic alcohol dehydrogenase and
its efficiency against alcoholism: vinegar effect. Alcohol Alcohol.
31:75–80. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pang H, Chen D, Cui QC and Dou QP: Sodium
diethyldithiocarbamate, an AIDS progression inhibitor and a
copper-binding compound, has proteasome-inhibitory and
apoptosis-inducing activities in cancer cells. Int J Mol Med.
19:809–816. 2007.PubMed/NCBI
|
|
27
|
Bradberry SM and Vale JA: Therapeutic
review: do diethyldi-thiocarbamate and disulfiram have a role in
acute nickel carbonyl poisoning? J Toxicol Clin Toxicol.
37:259–264. 1999. View Article : Google Scholar
|
|
28
|
Lövborg H, Oberg F, Rickardson L, Gullbo
J, Nygren P and Larsson R: Inhibition of proteasome activity,
nuclear factor-KappaB translocation and cell survival by the
antialcoholism drug disulfiram. Int J Cancer. 118:1577–1580. 2006.
View Article : Google Scholar
|
|
29
|
Zhang JJ, Xu ZM, Zhang CM, Dai HY, Ji XQ,
Wang XF and Li C: Pyrrolidine dithiocarbamate inhibits nuclear
factor-κB pathway activation, and regulates adhesion, migration,
invasion and apoptosis of endometriotic stromal cells. Mol Hum
Reprod. 17:175–181. 2011. View Article : Google Scholar
|
|
30
|
Han J, Liu L, Yue X, Chang J, Shi W and
Hua Y: A binuclear complex constituted by diethyldithiocarbamate
and copper(I) functions as a proteasome activity inhibitor in
pancreatic cancer cultures and xenografts. Toxicol Appl Pharmacol.
273:477–483. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dalla PE, Donadelli M, Costanzo C,
Zaniboni T, Dando I, Franchini M, Arpicco S, Scarpa A and Palmieri
M: Gemcitabine response in pancreatic adenocarcinoma cells is
synergistically enhanced by dithiocarbamate derivatives. Free Radic
Biol Med. 50:926–933. 2011. View Article : Google Scholar
|
|
32
|
Wei X, Du ZY, Cui XX, Verano M, Mo RQ,
Tang ZK, Conney AH, Zheng X and Zhang K: Effects of cyclohexanone
analogues of curcumin on growth, apoptosis and NF-κB activity in
PC-3 human prostate cancer cells. Oncol Lett. 4:279–284.
2012.PubMed/NCBI
|
|
33
|
Tsunoda T, Ishikura S, Doi K, Matsuzaki H,
Iwaihara Y and Shirasawa S: Resveratrol induces luminal apoptosis
of human colorectal cancer HCT116 cells in three-dimensional
culture. Anticancer Res. 34:4551–4555. 2014.PubMed/NCBI
|
|
34
|
Akeda K, Nishimura A, Satonaka H, Shintani
K, Kusuzaki K, Matsumine A, Kasai Y, Masuda K and Uchida A:
Three-dimensional alginate spheroid culture system of murine
osteosarcoma. Oncol Rep. 22:997–1003. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang Z and Rigas B: NF-κB, inflammation
and pancreatic carcinogenesis: NF-κB as a chemoprevention target
(Review). Int J Oncol. 29:185–192. 2006.PubMed/NCBI
|
|
36
|
Hu YQ, Si LJ, Ye ZS, Lin ZH and Zhou JP:
Inhibitory effect of ARHI on pancreatic cancer cells and NF-κB
activity. Mol Med Rep. 7:1180–1184. 2013.PubMed/NCBI
|
|
37
|
Kwon OH, Kim JH, Kim SY and Kim YS:
TWEAK/Fn14 signaling mediates gastric cancer cell resistance to
5-fluorouracil via NF-κB activation. Int J Oncol. 44:583–590.
2014.
|
|
38
|
Kaewpiboon C, Srisuttee R, Malilas W, Moon
J, Kaowinn S, Cho IR, Johnston RN, Assavalapsakul W and Chung YH:
Extract of Bryophyllum laetivirens reverses etoposide resistance in
human lung A549 cancer cells by downregulation of NF-κB. Oncol Rep.
31:161–168. 2014.
|
|
39
|
Fujioka S, Son K, Onda S, Schmidt C,
Scrabas GM, Okamoto T, Fujita T, Chiao PJ and Yanaga K:
Desensitization of NFκB for overcoming chemoresistance of
pancreatic cancer cells to TNF-α or paclitaxel. Anticancer Res.
32:4813–4821. 2012.PubMed/NCBI
|
|
40
|
Zhang W, Chen H, Liu DL, Li H, Luo J,
Zhang JH, Li Y, Chen KJ, Tong HF and Lin SZ: Emodin sensitizes the
gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via
downregulation of NF-κB and its regulated targets. Int J Oncol.
42:1189–1196. 2013.PubMed/NCBI
|
|
41
|
Cui XX, Chang RL, Zheng X, Woodward D,
Strair R and Conney AH: A sensitive bioassay for measuring blood
levels of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients:
preliminary pharmacokinetic studies. Oncol Res. 13:169–174.
2002.
|
|
42
|
Gandara DR, Nahhas WA, Adelson MD,
Lichtman SM, Podczaski ES, Yanovich S, Homesley HD, Braly P, Ritch
PS, Weisberg SR, et al: Randomized placebo-controlled multicenter
evaluation of diethyldithiocarbamate for chemoprotection against
cisplatin-induced toxicities. J Clin Oncol. 13:490–496.
1995.PubMed/NCBI
|
|
43
|
Qazi R, Chang AY, Borch RF, Montine T,
Dedon P, Loughner J and Bennett JM: Phase I clinical and
pharmacokinetic study of diethyldithiocarbamate as a chemoprotector
from toxic effects of cisplatin. J Natl Cancer Inst. 80:1486–1488.
1988. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mashiba H and Matsunaga K: Augmented
inhibition of MethA tumor cell proliferation in combined use of
diethyldithiocarbamate with catalase or by a nondialysable fraction
from co-incubation. Toxicol Lett. 66:97–104. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Han YH, Moon HJ, You BR, Kim SZ, Kim SH
and Park WH: The effects of buthionine sulfoximine,
diethyldithiocarbamate or 3-amino-1,2,4-triazole on propyl
gallate-treated HeLa cells in relation to cell growth, reactive
oxygen species and glutathion. Int J Mol Med. 24:261–268.
2009.PubMed/NCBI
|
